Şunu aradınız:: iron deficiency anaemia (İngilizce - Maltaca)

anaemia not caused by iron deficiency
anemija mhux ikkawżata minn defiċjenza ta’ ħadid.

anaemia, iron deficiency anaemia, lymph node pain, lymphadenopathy, neutropenia, thrombocytopenia
anemija, anemija minħabba nuqqas ta’ ħadid, uġigħ fin-nodi limfatiċi, limfadenopatija, newtropenija, tromboċitopenja

iron deficiency anaemia is a common problem in patients with inflammatory bowel disease.
anemija tad-defiċjenza tal-ħadid hija problema komuni f’pazjenti bil-marda infjammatorja tal-musrana.

in all three studies, patients with ckd and iron deficiency anaemia were randomized to treatment with rienso or oral iron.
fit-tliet studji kollha, pazjenti b’ckd u b’anemija kkawżata minn defiċjenza ta’ ħadid kienu kazwali għall-kura b’rienso jew kura b’ ħadid orali.

before you were prescribed rienso, the doctor will have carried out a blood test to make sure that you have iron deficiency anaemia.
qabel ma tiġi preskritt rienso, it-tabib se jkun għamel test tad-demm biex jiżgura li inti għandek anemija kkawżata minn defiċjenza ta’ ħadid.

during dynepo therapy, absolute or functional iron deficiency may develop.
evalwazzjoni tal- livell tal- ħadid ’ g matul it- terapija b’ dynepo, tista ’ tiżviluppa defiċjenza assoluta jew funzjonali tal- ħadid.

rienso is indicated for the intravenous treatment of iron deficiency anaemia in adult patients with chronic kidney disease (ckd).
rienso huwa indikat għall-kura ġol-vini ta’ anemija kkawżata minn defiċjenza ta’ ħadid f’pazjenti adulti b’mard kroniku tal-kliewi (ckd).

three main studies involving 838 chronic kidney disease patients with iron deficiency anaemia have been carried out to compare rienso with an iron treatment taken by mouth.
saru tliet studji ewlenin li kienu jinvolvu 838 pazjent b’mard kroniku fil-kliewi b’anemija kkawżata minn defiċjenzja tal-ħadid sabiex rienso jitqabbel ma’ kura tal-ħadid meħuda mill-ħalq.

iron deficiency is a common cause of anaemia in patients with long-term kidney disease and is itself caused by many factors including the poor absorption of dietary iron from food.
id-defiċjenza tal-ħadid hija kawża komuni tal-anemija f’pazjenti b’mard fil-kliewi fit-tul u d-defiċjenza nnifisha tiġi kkawżata minn ħafna fatturi, inkluż l-assorbiment insuffiċjenti tal-ħadid djetetiku mill-ikel.

if you have iron overload (too much iron in your body). if your anaemia is not caused by iron deficiency.
jekk għandek ammont żejjed ta’ ħadid (ħadid żejjed fil-ġisem tiegħek). jekk l-anemija tiegħek mhux ikkawżata minn defiċjenza ta’ ħadid.

it must not be used in patients with evidence of excess iron in the body or in patients whose anaemia is not caused by iron deficiency.
m’għandux jintuża fuq pazjenti li jkollhom evidenza ta’ eċċess ta’ ħadid fil-ġisem jew fuq pazjenti b’anemija li ma tkunx ikkawżata minn defiċjenza tal-ħadid.

feraccru is indicated in adults for the treatment of iron deficiency anaemia (ida) in patients with inflammatory bowel disease (ibd) (see section 5.1).
feraccru huwa indikat fl-adulti għall-kura ta’ anemija kkawżata minn defiċjenza ta’ ħadid (ida) f’pazjenti b’mard infjammatorju tal-musrana (ibd) (ara sezzjoni 5.1).

in placebo controlled trials temporary iron deficiency was more pronounced in patients treated with neorecormon than in controls (see section 4.4).
fi provi kontrollati bil-plaċebo, defiċjenza temporanja ta’ ħadid deheret aktar f’pazjenti kkurati b’neorecormon meta mqabbla mal-gruppi ta’ kontroll (ara sezzjoni 4.4).

iron deficiencies should be treated prior to starting treatment with retacrit.
insuffiċjenza fil-ħadid għandha tkun ittrattata qabel ma jinbeda t-trattament b’retacrit.

before starting treatment, your doctor will use a blood test to make sure that your anaemia is not severe or caused by anything other than iron deficiency (low iron stores).
qabel tibda l-kura, it-tabib tiegħek ser juża test tad-demm biex ikun ċert li l-anemija tiegħek mhijiex gravi jew ikkawżata minn xi ħaġa oħra għajr defiċjenza ta’ ħadid (ħażniet baxxi ta’ ħadid).

if you, or your sexual partner, have been diagnosed with a genetic disease or other condition affecting your red blood cells (glucose-6-phosphate deficiency, anaemia or methaemoglobinaemia);
jekk inti, jew is-sieħeb/sieħba sesswali tiegħek, ġejtu dijanjostikati b’marda ġenetika jew b’kondizzjoni oħra li taffettwa ċ-ċelloli tad-demm ħomor (defiċjenza ta’ glucose 6 phosphate, anemija jew methaemoglobinaemia);

all other causes of anaemia (iron deficiency, haemolysis, blood loss, vitamin b12 or folate deficiencies) should be considered and treated prior to initiating therapy with epoetin alfa.
il- kawżi l- oħra kollha ta ’ anemija (defiċjenza ta ’ ħadid, l- emodijalisi, telf ta ’ demm, defiċjenza ta ’ vitamina b12 jew ta ’ folate) għandhom jiġu kkunsidrati u kkurati qabel ma tinbeda t- terapija b’ epoetin alfa.

feraccru was compared with placebo (a dummy treatment) in one main study involving 128 patients with inflammatory bowel disease who had iron deficiency anaemia, defined as haemoglobin levels below 12.0 grams per decilitre (g/dl).
feraccru tqabbel ma’ plaċebo (kura finta) fi studju ewlieni wieħed li involva 128 pazjent b’mard infjammatorju tal-musrana li kellhom anemija tad-defiċjenza ta' ħadid, definita bħala livelli tal- emoglobina inqas minn 12.0-il gramm għal kull deċilitru (g/dl).

all other causes of anaemia (iron deficiency, haemolysis, blood loss, vitamin b12- or folate deficiencies) should be considered and treated prior to initiating and during therapy with retacrit.
il-kawżi l-oħra kollha ta’ anemija (defiċjenza fil-ħadid, emolisi, telf ta’ demm, vitamina b12 jew defiċjenzi fil-folates) għandhom jiġu kkunsidrati u ttratati qabel il-bidu u waqt it-terapija b’retacrit.

treatment should only be given to patients with moderate anaemia (hb 10 - 13 g/dl [6.21 - 8.07 mmol/l], no iron deficiency) if blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).
il-kura għandha tingħata biss lil pazjenti b’anemija moderata (hb 10 - 13 g/dl [6.21 - 8.07 mmol/l], mingħajr defiċenza ta’ ħadid) jekk ma jkunx hemm proċeduri biex jippreservaw id-demm jew jekk dawn il-proċeduri ma jkunux tajbin biżżejjed meta trid issir operazzjoni maġġura, mhux urġenti li jkollha bżonn ammonti kbar ta’ demm (4 unitajiet jew iżjed għan-nisa jew 5 unitajiet jew iżjed għall-irġiel).